Ablation assets
This article was originally published in The Gray Sheet
Executive Summary
CryoCath inks $10 mil. deal to acquire Endocare's cardiac-related product manufacturing operations in Irvine, Calif. The sale is subject to Endocare's clearing certain manufacturing and R&D milestones in 2003. Terms include the exclusive licensing of the Surgifrost cryoablation system to CryoCath in exchange for a nine-year descending royalty stream based on net sales. The deal represents the latest move by Endocare to divest non-core assets to concentrate resources on its Cryocare prostate cancer platform (1"The Gray Sheet" April 14, 2003, p. 27). SurgiFrost was developed through a partnership between the two companies and was approved to treat cardiac arrhythmias in February 2002 (2"The Gray Sheet" Feb. 3, 2003, p. 20)...
You may also be interested in...
Endocare To Shed Non-Core Assets, Focus On Cryocare Indications
Endocare is divesting "certain non-core" assets in order to concentrate resources on expanding adoption of its Cryocare prostate cancer platform and pursuit of additional applications
CryoCath Looks To Ice Atrial Fibrillation, Flutter With Cryoablation Therapies
CryoCath aims to place its Freezor cryoablation catheter in 300 centers by year-end, pending PMA approval of the supraventricular tachycardia treatment device
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.